Serum therapy revisited: animal models of infection and development of passive antibody therapy.
about
Vaccines for preventing pneumococcal infection in adultsVaccines for preventing pneumococcal infection in adultsModulation of the lung inflammatory response to serotype 8 pneumococcal infection by a human immunoglobulin m monoclonal antibody to serotype 8 capsular polysaccharide.Use of licensed vaccines for active immunization of the immunocompromised hostThe forgotten forefather: Joseph James Kinyoun and the founding of the National Institutes of HealthMonoclonal antibody-based therapies for microbial diseasesTherapeutic antibodies: current state and future trends--is a paradigm change coming soon?Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening.Murine IgG1 and IgG3 isotype switch variants promote phagocytosis of Cryptococcus neoformans through different receptorsProduction of recombinant antibodies using bacteriophages.Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsuleBivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule.Molecular and functional characteristics of a protective human monoclonal antibody to serotype 8 Streptococcus pneumoniae capsular polysaccharide.Prophylactic and therapeutic efficacy of antibodies to a capsular polysaccharide shared among vancomycin-sensitive and -resistant enterococci.Structure-function relationships for human antibodies to pneumococcal capsular polysaccharide from transgenic mice with human immunoglobulin Loci.Prospects for development of a vaccine to prevent and control vaginal candidiasis.Passive antibody administration (immediate immunity) as a specific defense against biological weapons.Measuring the quality of clinical veterinary services for Cattle: an application of a role play experiment in rural UgandaAntibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle.Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophagesEvaluation of humoral and cell-mediated inducible immunity to Haemophilus ducreyi in an animal model of chancroidOpsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodiesAdvances in antibody-mediated immunity against Mycobacterium tuberculosis: implications for a novel vaccine strategy.History of passive antibody administration for prevention and treatment of infectious diseases.Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.Passive antibody therapy for infectious diseases.Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection.Monoclonal antibodies and toxins--a perspective on function and isotype.Capsular polysaccharide-protein conjugate vaccines and intravenous immunoglobulins.Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant.The potential of antibody-mediated immunity in the defence against biological weapons.Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses.Parasites and immunotherapy: with or against?Efficacy of opsonic and nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibodies against intranasal challenge with Streptococcus pneumoniae in mice.Vaccine immunology.Novel strategies for controlling Streptococcus pyogenes infection and associated diseases: from potential peptide vaccines to antibody immunotherapy.Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology.Feasibility of radioimmunotherapy of experimental pneumococcal infection.Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates.A multifunctional bispecific antibody protects against Pseudomonas aeruginosa.
P2860
Q24201474-4298A8C3-890F-44FC-AC49-AC96AE3B83FCQ24242290-2FA4AB32-832A-4858-B435-A9CF8469794BQ24532019-AB18F3D7-ECB4-49DD-9475-177648587205Q24533456-869E69FD-E0C0-4696-ACAA-E61AD0A3058DQ26862110-5922EC61-D6BE-4C46-B893-CF327AC0B76AQ27490830-76EEEA03-54C5-41C7-95A1-7007F031C2C1Q28728956-F671D2FA-578D-42E3-8C6C-F9227A069EE7Q30423024-D9877F88-6D1B-4EE5-BF26-2411DFD1862BQ33562297-C454E3D8-59F1-498C-952C-450B09143E9BQ33643027-7AAAA3E8-6C14-48A1-8914-8D99B3039B4FQ33752366-D3DBFB31-DBA9-466E-89AF-E4620F5D3E59Q33752377-4387FB94-EBC6-41C7-9531-440655B22B3BQ34001504-A0D65116-0B92-43B2-8870-1509A1A4076AQ34007780-4CCC025D-F079-4BD3-A31A-2CA0162C2D46Q34130657-F2B4D81D-13E6-47E8-8D10-7D327E81E566Q34707478-343ED4C4-AD3B-45DA-9C55-C2F08971E80BQ34762095-04CF408D-D1DE-4CC9-B613-CAFD89B83387Q34968019-50C58ED1-712F-440F-B1E4-9564E2CE91D5Q35182322-CFF07F89-8C31-4478-9ADE-7AF436334DA1Q35386000-7ED9FD13-AC76-48C3-9C52-2C99C69005EFQ35491271-95DB2C3D-F89D-4E0D-B00D-37C7F4A9B3C7Q35514947-75DED2D3-AF30-41AF-9BA5-A7974CF164FDQ35558612-9833D233-B580-4686-8043-F72CFF2BDEB5Q35624143-CF1DA4C8-C6E8-485F-927C-154DE366FF1AQ35783722-F6EE1DF3-5B52-4746-868B-C697425D530FQ35889582-5B4DBF07-171F-454C-82BA-B45CE3037234Q35978710-B2F6C3CE-CF22-48F5-AC04-37B5AF41D758Q36099489-255E52CF-8167-40E2-80E1-3D04D144717CQ36181172-D0633007-DB02-4CA6-8EFC-B06B202C26E7Q36183762-9C9B7614-EF7A-409E-9EBE-6B04CC93783EQ36273411-52E5D09C-D2DA-4E6D-9297-637D84A15751Q36379337-DF6D31FF-9F3E-4301-AD61-E8175A41954EQ37053248-33155CDB-15BB-4EB3-8C2E-38B16E69FA33Q37145037-91A4AECB-B135-4057-ADEE-07B7E344A098Q37427999-212C2286-38CE-4024-B9E9-3A3DF89C382CQ37471470-4772C29B-D2FE-4D1C-8079-5A6C962591C2Q37626123-76A02936-B44D-4197-9E30-B99ACC332C08Q37734799-82C657B8-E4EB-462A-9AE9-1F34564C1FABQ38212929-D3D7AB2B-C241-484B-8B40-C8B2003EB1D6Q38940907-1CAF3A6F-659F-406B-963F-F2DCAFBC80F3
P2860
Serum therapy revisited: animal models of infection and development of passive antibody therapy.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Serum therapy revisited: anima ...... t of passive antibody therapy.
@en
type
label
Serum therapy revisited: anima ...... t of passive antibody therapy.
@en
prefLabel
Serum therapy revisited: anima ...... t of passive antibody therapy.
@en
P2860
P356
P1476
Serum therapy revisited: anima ...... t of passive antibody therapy.
@en
P2093
A Casadevall
M D Scharff
P2860
P304
P356
10.1128/AAC.38.8.1695
P407
P577
1994-08-01T00:00:00Z